Clinical Trial

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-08; most recent amendment 2025-05-28.
Status change: Not Yet Recruiting → Recruiting 2024-03-19
Trial Details
NCT Number NCT06130579
Lead Sponsor Peking University People's Hospital
Conditions Myeloid Leukemia, Myelodysplastic Syndromes
Enrollment 35 participants
Start Date 2024-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-03